Preclinical Trials
Salarius Pharmaceuticals
A preclinical pharmacokinetics, pharmacodynamics and survival analysis of Seclidemstat in glioblastoma PDX models. This study will evaluate the effect of targeting LSD1 (lysine-specific histone demethylase 1A), a key enzyme that has increased expression in tumors of brain cancer patients.
Preclinical study in progress
Testing first-in-class investigational therapy seclidemstat
Karyopharm Therapeutics
We are testing Karyopharm’s first-in-class oral Selective Inhibitor of Nuclear Export (SINE) compound, selinexor, in combination with other new-in-class drugs, as a dual-drug experimental therapy for adult glioblastoma.
Preclinical study in progress
Preclinical study targeting XP01 in glioblastoma
QED Therapeutics and Columbia
A pharmacokinetic and pharmacodynamic assessment of FGFR inhibitor, infigratinib, for the treatment of glioblastoma. This collaboration focuses on targeting FGFR (fibroblast growth factor receptor) genetic alterations that have been shown to spur growth in malignant tumors.
Preclinical study in progress
Testing investigational agent infigratinib in glioblastoma
Eli Lilly
A preclinical pharmacokinetics, pharmacodynamics and survival analysis of Aurora kinase inhibitor in glioblastoma PDX models.
Preclinical study in progress
Testing aurora kinase inhibitor